1. GPCR/G Protein
    Immunology/Inflammation
  2. CCR

CCR

CCR (Chemokine receptors) are cytokine receptors found on the surface of certain cells that interact with a type of cytokine called achemokine. There have been 19 distinct chemokine receptors described in mammals. Each has a 7-transmembrane (7TM) structure and couples to G-protein for signal transduction within a cell, making them members of a large protein family of G protein-coupled receptors. Following interaction with their specific chemokine ligands, chemokine receptors trigger a flux in intracellular calcium (Ca2+) ions (calcium signaling). This causes cell responses, including the onset of a process known as chemotaxis that traffics the cell to a desired location within the organism. Chemokine receptors are divided into different families, CXC chemokine receptors, CC chemokine receptors, CX3C chemokine receptors and XC chemokine receptors that correspond to the 4 distinct subfamilies of chemokines they bind. Specific chemokine receptors provide the portals for HIV to get into cells, and others contribute to inflammatory diseases and cancer.

CCR Related Products (31):

Cat. No. Product Name Effect Purity
  • HY-13004
    Maraviroc Antagonist 99.71%
    Maraviroc is a selective CCR5 antagonist, inhibits MIP-1α (IC50, 3.3 nM), MIP-1β (IC50, 7.2 nM), and RANTES (IC50, 5.2 nM) binding to cell membrane preparations of CCR5-expressing HEK-293.
  • HY-50674
    INCB3344 Antagonist 99.76%
    INCB3344 is a potent CCR2 antagonist with IC50 values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.
  • HY-13245
    PF-4136309 Antagonist 99.59%
    PF-4136309 is a potent, selective, and orally bioavailable CCR2 antagonist, with IC50 of 5.2 nM, 17 nM and 13 nM for human, mouse and rat CCR2.
  • HY-14882
    Cenicriviroc Antagonist
    Cenicriviroc is an orally active, dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.
  • HY-12080
    BX471 Antagonist
    BX471 is a potent, selective non-peptide CCR1 antagonist with Ki of 1 nM for human CCR1, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.
  • HY-112792
    CCR2 antagonist 1 Antagonist
    CCR2 antagonist 1 is a high-affinity and long-residence-time CCR2 antagonist, with a Ki of 2.4 nM.
  • HY-17450
    Aplaviroc Antagonist
    Aplaviroc, a SDP derivative, is a CCR5 antagonist, with IC50s of 0.1-0.4 nM for HIV-1Ba-L, HIV-1JRFL and HIV-1MOKW.
  • HY-107051
    GW 766994 Antagonist
    GW 766994 is a specific and oral chemokine receptor-3 (CCR3) antagonist, which has entered clinical trial for asthma and eosinophilic bronchitis.
  • HY-15418
    RS 504393 Antagonist 98.58%
    RS 504393 is a selective CCR2 chemokine receptor antagonist (IC50 values are 89 nM and > 100 μM for inhibition of human recombinant CCR2 and CCR1 receptors respectively).
  • HY-18611
    RS102895 hydrochloride Antagonist 98.98%
    RS102895 hydrochloride is a potent CCR2 antagonist, with an IC50 of 360 nM, and shows no effect on CCR1.
  • HY-15724
    Vercirnon Antagonist 98.04%
    Vercirnon is an orally bioavailable, selective, and potent antagonist of CCR9, with an IC50 of 10 nM, used in the research of inflammatory bowel diseases.
  • HY-13406
    TAK-779 Antagonist 99.73%
    TAK-779 is a potent and selective nonpeptide antagonist of CCR5 and CXCR3, with a Ki of 1.1 nM for CCR5, and effectively and selectively inhibits R5 HIV-1, with EC50 and EC90 of 1.2 nM and 5.7 nM, respectively, in MAGI-CCR5 cells.
  • HY-14882A
    Cenicriviroc Mesylate Antagonist 98.23%
    Cenicriviroc is a dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.
  • HY-50669A
    MK-0812 Succinate Antagonist 99.57%
    MK-0812 Succinate is a potent and selective CCR2 antagonist with high affinity at CCR2 on human monocytes.
  • HY-15450A
    INCB 3284 Antagonist 99.30%
    INCB 3284 is a potent, selective and orally bioavailable human CCR2 antagonist, inhibiting monocyte chemoattractant protein-1 binding to hCCR2, with an IC50 of 3.7 nM. INCB 3284 can be used in the research of acute liver failure.
  • HY-U00064
    AZD2098 Inhibitor 99.85%
    AZD2098 is a potent CC-chemokine receptor 4 (CCR4) inhibitor, used for asthma research.
  • HY-17377
    Vicriviroc maleate Antagonist 99.41%
    Vicriviroc maleate is a potent, selective, oral bioavailable and CNS penetrated antagonist of CCR5, with a Ki of 2.5 nM, and also inhibits HIV-1 in PBMC cells, with IC90s of 3.3 nM (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), 4.9 nM (JV1083) and 10 nM (RU 570).
  • HY-109593
    BMS-813160 Antagonist 99.81%
    BMS-813160 is the first dual CCR2/CCR5 antagonist to enter clinical development for cardiovascular.
  • HY-19974
    TAK-220 Antagonist >98.0%
    TAK-220 is a selective and orally bioavailable CCR5 antagonist, with IC50s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively, but shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4, or CCR7; TAK-220 also selectively inhibits HIV-1, with EC50s of 1.2 nM (HIV-1 KK), 0.72 nM (HIV-1 CTV), 1.7 nM (HIV-1 HKW), 1.7 nM (HIV-1 HNK), 0.93 nM (HIV-1 HTN), and 0.55 nM (HIV-1 HHA), and EC90s of 12 nM (HIV-1 KK), 5 nM (HIV-1 CTV), 12 nM (HIV-1 HKW), 28 nM (HIV-1 HNK), 15 nM (HIV-1 HTN), and 4 nM (HIV-1 HHA) in PBMCs.
  • HY-P1034
    DAPTA Inhibitor 98.73%
    DAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively CCR5, and shows potent anti-HIV activities. Sequence: Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-NH2 .